Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy
NCT07343596Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab in oral cavity cancer (OCC), sponsored by University of Wisconsin–Madison. Primary endpoints: Changes in Gene Expression at 2 months, Phenotypic Changes in the Immune Microenvironment at 2 months and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
oral cavity cancer (OCC)
Beyond the preview
Go deeper on NCT07343596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343596.